Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"We've actively engaged with multiple large pharmas, who have expressed an interest in Brilacidin inflammatory bowel disease. The pharma industry is quite interested in pursuing novel IBD therapies one of the more active therapeutic areas when it comes to dealmaking."
"In the meantime, we can say that big pharma knows that we know there's tremendous value in our pipeline. They know that. We work daily to position our product to command the higher value. The good news is that data will start streaming in very shortly. The bottom line is assuming the data is in line with previous data or interim results, we feel there are opportunities for partnering."
"All the conversations have been productive and as we approach additional readouts, I'd imagine that they're only going to get more active. Active partnership versus acquisition on possible exits, we plan to keep an open mind should opportunities present themselves."
"We had said that confidential disclosure agreements have been signed with several pharmas interested in our drug candidates; to some, they're interested in one compound. Others have requested information on a combination of Brilacidin and Kevetrin and Prurisol."
"Companies will pay what the drug is worth to them. Our job when it comes to partnering is to get our pipeline far enough along to present positive datasets to several potential partners and go from there. That's the point we are at currently."
This week begins the ascent. 4 weeks f/u for OM completes next week.
Couldn't agree more. Our time is a-coming!
I really think that those 58% odds are an objective number...
But for IPIX, we have to be a bit more subjective...
B-OM already has interim analysis out....PLUS...Leo has stated if OM works, they are nearly certain UP would work...UP worked, so the logic implies OM will work. Safety has been established in the ABSSSI trials...this adds up to > 58% odds for B-OM
K was a 1b, and has had an observable effect on OV cancer cells, which have the highest percentage of P53 damage... and they are targeting OV cancer in the phase 2 trial. K was safe enough that MAD was declared as MTD.
P has already completed a phase 2a and is a pro-drug of an existing approved drug.
According to my calculations, B-OM 4 weeks follow up ends next week. WOW, did I just say NEXT WEEK??!!
I don't think this post is factual regarding IPIX. Why is it stickied?
I think you made the right decision to go hide in the bushes while things play out this morning. A lot of people were caught flat-footed this morning. When you and team have revised your strategy, come back and play some more.
You should read post 198526. Apparently you were caught flat-footed and not aware of what an incredible drug Prurisol could be....
I think a lot of players were caught flat-footed this weekend. Surprise positive news story for those who search the stickies on the top of the list.
WOW! Thanks for sharing... prurisol is worth at least 10 billion dollars!!!
The best part is the OM results are a lock. IPIX will still be batting 100%. Counting down the days!
Agreed! Thanks.
Patient enrollment announcement was aug 7th. Today completes the 7th week from that announcement (unless you want to venture someone is finishing up over the weekend). 11 weeks (7+4) will be through Oct 20th.
Press Release: Innovation Pharmaceuticals Completes Patient Enrollment in Phase 2 Study of Brilacidin for the Prevention of Severe Oral Mucositis
BEVERLY, Mass., August 7, 2017 (GLOBE NEWSWIRE) – Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that it has completed patient enrollment for its ongoing Phase 2 clinical study of Brilacidin for the prevention of Severe Oral Mucositis (OM). A total of 61 patients have been enrolled, with topline results anticipated in 4Q2017.
7 weeks of treatment through today...now we wait for the 4 weeks of post-treatment follow up. If you come up with a different date, please let me know!
Congratulations! B-OM dosing is complete... let's count down the weeks till this trial is finished.
back online.
Looks that way to me.
Slide 5 - "Near-Term Catalysts by Year-End—trial completion, results reporting;
collaboration/partnership opportunities"
Pete,
I have a hunch this is more to do with getting the Prurisol trial completed by year end...
If you count out the 16 weeks from Sept 1, you get Dec. 22nd.
Then, if you take Leo's email to cabel at face value, the slow enrollment pushed the completion date back. So, Leo probably had the choice to request the interim data, but at the risk of increased trial investigator bias. The remedy to get the risk back within range would be to increase enrollment further. But if he did, then he would have the much bigger issue to deal with, which is ultimately having to change the trial completion date to 2018. So he chose to forgo the interim data to keep us on schedule for the whole trial.
Nice article. Thanks!
I'm so glad that even if you do just a little bit of DD, you can see how IPIX has designed the P 2b trial to show statistical significance, rendering doubt unwarranted.
Fake news!
Don't believe me?...maybe you should read the disclaimer on the bottom of the page...
"all information and blog posts found on this site is to be viewed for entertainment purposes only and is to be considered fake news even if it is actually happening or happens!"
Nice! Thanks for posting
By George, I think you might be right!
You bet, bud. Anytime.
It wasn't a bid deal then, it's not a big deal now...
BEVERLY, MA--(Marketwired - January 25, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that approximately 75 percent of the subjects enrolled in the Company's Phase 2 clinical trial of Prurisol for the treatment of chronic plaque psoriasis have completed dosing, defined as 84 days of daily treatments of Prurisol or placebo. The subjects will now be followed for an additional 4 weeks, without taking any further study medication.
The four-arm multi-center Phase 2 trial, three arms with different dosing regimens of Prurisol and one arm placebo, is designed to assess the efficacy and safety of Prurisol given orally compared to placebo in a randomized, double-blind setting in patients with mild to moderate chronic plaque psoriasis. The trial was expected to enroll 100 subjects and actually enrolled 115 subjects. The primary efficacy endpoint will be the percentage of subjects with greater than or equal to a 2-point improvement in Investigator's Global Assessment (IGA) rating as defined by visual inspections of patient lesions. The final study visit for the last subject is expected early in April 2016, with top-line data anticipated approximately four weeks later.
cabel, in the phase P 2a trial, they over-enrolled, too... (in the OM trial, they over-enrolled 61 vs 60).
Anyone making a big deal about this or even suggesting that this is for the 400mg group is just speculating...
I think that kind of speculating is counterproductive.
I think you are confusing B-OM with B-UP. UP was open label, OM is double blinded, placebo controlled. So to Cabal's point, we got interim results for OM, which seems to go against your logic.
Also, we are not SPECULATING if we should interim results for P, WE WERE TOLD BY MANAGEMENT ON AT LEAST 2 OCCASIONS AND IT'S ON THE COMPANY TIMELINE.
Be safe, bud!
Biohedge...posts like these are good to keep everyone grounded and thanks for the topic.
All this talk of partnership started early in the year...imo, 2 changes to timelines occurred. 1) P trial enrollment went at a slower pace than anticipated. It was my belief that IPIX would partner this first. 2) B-OM enrollment accelerated must faster than anticipated.
I think the combination of these two events will change the order for partnering. I'm sure Leo and Co. are focused on landing a deal for year end, but now I'm starting to think that partnership will be for B, but only because the OM trial will have top line data first.
To me the single most important corporate objective is having sufficient funds for all the indications of B. In my opinion, a small UP deal gets us there, a medium P deal or a medium OM deal will be more than enough.
Approximately 189 study participants will be enrolled. Subjects will be randomly assigned to one of three treatment groups in a 3:3:1 randomization ratio, respectively.
Group A (n=81): Prurisol 150 mg bid
Group B (n=81): Placebo
Group C (n=27): Prurisol 200 mg bid
https://clinicaltrials.gov/ct2/show/NCT02949388?term=cellceutix&rank=4
PS. "bid" means twice/day
I just re-read that yesterday and it gives me confidence in my safety expectations for the P trial.
I registered for the NewsMakers conference. If you go through the registration process, they have several different "types" of registrants. Though none of them really fit me a an individual investor, some of have a $600 charge for attending, while others are $0. So I registered as a $0 type.
Because it is a Friday, in the end I might not be able to make it, but wanted to at least make an attempt. I haven't gotten a confirmation email yet, so I'm not sure if they vet your application first. I'm interested if anyone else has gone through the registration process yet and/or plans on attending.
Just want to provide some logic:
According to Clinical Trials for Prurisol:
"A subject studied under this clinical protocol will commence with a screening period of up to 4 weeks, a treatment period of 12 weeks, and a follow-up period of 4 weeks ending with an End of Study evaluation."
4+12+4= 20 weeks
From the PR today: "We will also highlight the major events upcoming for us in the fourth quarter, namely anticipated completion of our Phase 2 trials of Brilacidin-OM for oral mucositis and Prurisol for psoriasis"
When I start with 12/31/17 and count back 20 weeks, I get August 13th. To me, this means that ALL 189 participants are at least going through screening.
And since that PR, they have added 6 new recruitment sites.
Great post flash! Always keeping things real